Abstract:OBJECTIVETo investigate the patterns of spasmodic dysphonia and the outcome treated with botulinum toxin A injections.METHODSAll subjects were studied with acoustic analysis, laryngostroboscopy and laryngeal electromyography (EMG) including motor unit potential measure (MUP), recruitment pattern analysis and evoked electromyography. All the patients with spasmodic dysphonia were received botulinum toxin A (BOTOX) injections in each affected muscles and mostly under electromyographic guidance.RESULTSAmong 22 cases of spasmodic dysphonia, 18 cases of adductor dysphonic patients have strained, strangled voice with intermittent breaks in speech as a consequence of hyperadduction and spasm of the vocal folds during phonation. Two patients had synchronous pharyngeal, lingual and velar tremor. Amplitudes of MUP of thyroarytenoid muscle (TA) were greater in patients group than in normal group (P < 0.01); The recruitment activity was increased and the amplitudes were greater than normal group (700-2500 microV) and the duration of activity of the TA during phonation was also notably greater in patients group than in normal group. Four cases of abductor dysphonic patients have a breathy, effortful hypophonic voice with abrupt termination of voicing. Amplitudes of MUP of posterior cricoarytenoid muscle (PCA) in patients group were increased up to 374 to 538 microV. The recruitment activity was increased and the amplitude was greater than normal(3000-5000 microV). In the adductor dysphonic group, patients who were treated with unilateral toxin injection had good results with 2.5 U or more. The average onset of toxin effect in all adductor dysphonic patients was at 6 hours to 2 days (1.4+/-0. 8) days (x +/- s), with a peak effect at 2 weeks and the follow-up EMG showed fibrillation potentials or electric silence in injected muscle. Duration of benefit was 8 to 24 weeks (15.2 +/- 4.9) weeks. The side-effect of toxin injection were including breathy voice or occasional dysphagia and aspiration. The patients with abductor spasms were less well controlled after PCA injections.CONCLUSIONSSpasmodic dysphonia was regarded as a neuromuscular diseases, so its diagnosis, classification, treatment and follow-up should depend on not only clinical manifestation but also EMG. Presently, for controlling the dystonic symptoms, the most effective therapy for most of those patients is local BOTOX injections. Repeated injections are required to have a stable results.

Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome

Exploring Biomechanical Correlates in Voice Analysis of Multiple Sclerosis Patients

The role of laryngoscopy in the diagnosis of spasmodic dysphonia

Value of Laryngeal Electromyography in Spasmodic Dysphonia Diagnosis and Therapy

A Presentation of Meige Syndrome With Associated Upper Motor Neuron Symptoms

Pallidal deep brain stimulation in the treatment of Meige syndrome

[Analysis of vocal fold vibration characteristics of spasmodic dysphonia by laryngeal high speed photography combined with glottis area wave]

Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update

Management of Meige Syndrome with Bilateral Trigeminal and Facial Nerves Combing

Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment

CT-guided radiofrequency ablation of the extracranial cranial nerve for the treatment of Meige's syndrome

Unilateral Stereotactic Radiofrequency Lesioning as a Surgical Treatment Option for Meige Syndrome

Historical approaches to the treatment of Adductor-Type Spasmodic Dysphonia (ADSD): Review and tutorial

Breathing dystonia in Meige syndrome

Effects of onabotulinum toxin type A injections in patients with Meige's syndrome

Oral findings and comprehensive dental management of Moebius syndrome: a systematic review

Subjective voice analysis in patients with muscular tension dysphonia: comparison between clinician and patient evaluation

Massage and Vocal Training in A Case of Spasmodic Dysphonia

[Patterns of Spasmodic Dysphonia and Botulinum Toxin Injections].

Comparing dysphonia severity index, objective, subjective, and perceptual analysis of voice in patients with multiple sclerosis and healthy controls

Tremor Makes a Difference: A Comparative Study of the Demographics and Treatment Outcomes in Patients With Adductor Spasmodic Dysphonia With or Without Vocal Tremor